Published in BMC Cancer on March 12, 2010
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res (2011) 2.12
Environmental chemical exposures and human epigenetics. Int J Epidemiol (2011) 1.97
Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. PLoS One (2011) 1.27
Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium. Clin Cancer Res (2010) 1.05
Aberrant promoter CpG methylation and its translational applications in breast cancer. Chin J Cancer (2011) 0.90
Assessment of DNA methylation status in early stages of breast cancer development. Br J Cancer (2013) 0.88
Comparison of methylation profiling in cancerous and their corresponding normal tissues from korean patients with breast cancer. Ann Lab Med (2013) 0.87
Quantitative assessment of the association between APC promoter methylation and breast cancer. Oncotarget (2016) 0.76
RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA. Oncotarget (2017) 0.75
Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. BMC Cancer (2017) 0.75
Multiple biological functions of Twist1 in various cancers. Oncotarget (2017) 0.75
Quantitative and correlation analysis of the DNA methylation and expression of DAPK in breast cancer. PeerJ (2017) 0.75
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer (1953) 11.45
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet (1994) 8.34
MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst (2005) 5.22
Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res (1998) 4.39
Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science (1996) 3.54
Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res (2006) 2.70
Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res (2002) 2.56
Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res (2004) 2.29
Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res (2001) 2.18
Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res (2003) 2.03
Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res (2007) 2.02
Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci U S A (1996) 1.99
Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res (2005) 1.93
Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res (2004) 1.93
Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene (2001) 1.89
Epigenetic field for cancerization. J Biochem Mol Biol (2007) 1.73
Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol (2002) 1.68
DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev (2008) 1.68
Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol (2003) 1.65
Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res (2001) 1.52
Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res (2001) 1.51
DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett (2005) 1.48
Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev (2009) 1.43
Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res (2004) 1.31
Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa. Br J Cancer (2008) 1.27
RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat (2008) 1.20
DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2008) 1.19
Outer breast quadrants demonstrate increased levels of genomic instability. Ann Surg Oncol (2004) 1.08
Aberrant methylation of the maspin promoter is an early event in human breast cancer. Neoplasia (2004) 1.05
Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. Clin Cancer Res (2007) 1.05
GSTP1 promoter hypermethylation is an early event in breast carcinogenesis. Virchows Arch (2007) 1.05
DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2'-deoxycytidine. Anticancer Drugs (1999) 1.01
Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Res Treat (2007) 0.99
Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype. Br J Cancer (2008) 0.95
Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis. Cancer Biol Ther (2008) 0.93
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2010) 5.01
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 4.12
Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. J Natl Cancer Inst (2014) 2.37
Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer (2003) 2.36
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol (2010) 2.34
VHL and HIF signalling in renal cell carcinogenesis. J Pathol (2010) 2.13
Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res (2004) 2.12
Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis. Eur J Cancer (2012) 2.07
mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res (2011) 1.66
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res (2004) 1.59
Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res (2006) 1.58
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res (2011) 1.56
Mechanism of tumour vascularization in experimental lung metastases. J Pathol (2014) 1.55
Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes. Cancer Biol Ther (2009) 1.55
Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res (2012) 1.39
The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat (2003) 1.36
The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res (2013) 1.35
Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat (2005) 1.34
Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer (2002) 1.33
Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res (2013) 1.30
Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat (2005) 1.29
Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS One (2010) 1.26
Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res (2005) 1.24
Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat (2005) 1.24
Increased sentinel lymph node lymphangiogenesis is associated with nonsentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node. Clin Cancer Res (2007) 1.22
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer (2012) 1.17
Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge. Cancer (2010) 1.14
Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res (2015) 1.12
Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer. Clin Cancer Res (2008) 1.10
The histological growth pattern of colorectal cancer liver metastases has prognostic value. Clin Exp Metastasis (2012) 1.03
Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer. Clin Cancer Res (2008) 0.98
Regulation of inflammatory breast cancer cell invasion through Akt1/PKBα phosphorylation of RhoC GTPase. Mol Cancer Res (2012) 0.97
Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. J Clin Oncol (2013) 0.96
Differential expression of hypoxia and (lymph)angiogenesis-related genes at different metastatic sites in breast cancer. Clin Exp Metastasis (2007) 0.94
Inflammatory breast cancer: current understanding. Curr Opin Oncol (2006) 0.94
Is there a role for mammary stem cells in inflammatory breast carcinoma?: a review of evidence from cell line, animal model, and human tissue sample experiments. Cancer (2010) 0.92
The interaction between ER and NFκB in resistance to endocrine therapy. Breast Cancer Res (2012) 0.90
Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. Breast Cancer Res (2005) 0.90
Early repolarization in mice causes overestimation of ventricular activation time by the QRS duration. Cardiovasc Res (2012) 0.87
Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers. Eur J Cancer (2005) 0.87
Prognostic significance of disseminated tumor cells as detected by quantitative real-time reverse-transcriptase polymerase chain reaction in patients with breast cancer. Clin Breast Cancer (2006) 0.87
Detection of circulating tumour cells in blood by quantitative real-time RT-PCR: effect of pre-analytical time. Clin Chem Lab Med (2006) 0.85
Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. PLoS One (2011) 0.84
PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor. Bone (2006) 0.84
Regulation of alcohol oxidase 1 (AOX1) promoter and peroxisome biogenesis in different fermentation processes in Pichia pastoris. J Biotechnol (2013) 0.84
A dynamic clinical pathway for the treatment of patients with early breast cancer is a tool for better cancer care: implementation and prospective analysis between 2002-2010. World J Surg Oncol (2013) 0.84
Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer. J Clin Pharmacol (2006) 0.81
A low frequency of lymph node metastasis in clear-cell renal cell carcinoma is related to low lymphangiogenic activity. BJU Int (2009) 0.80
Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial. Arch Pathol Lab Med (2016) 0.80
Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer (2009) 0.80
Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst (2009) 0.80
Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene. Cell Oncol (2009) 0.80
Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastases. J Oncol (2012) 0.78
Sentinel node detection in patients with vaginal carcinoma. Gynecol Oncol (2004) 0.77
Endothelial cell apoptosis in the context of quantification of angiogenesis in solid human adenocarcinomas: a novel double immunolabelling technique to identify endothelial cell apoptosis. Eur J Cancer (2005) 0.77
Sentinel node metastasis in the groin detected by technetium-labeled nannocolloid in a patient with cervical cancer. Gynecol Oncol (2002) 0.77